All In Biotech

Drug Trial Radar · NCT07855172

Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib)

A Phase I/II, Double-Blind, Randomized, Active Controlled, Multi-centric Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Recombinant Poliomyelitis and Haemophilus Influenzae Type b (Hib) Vaccine (SIIPL DTwP-HepB-rPV-Hib) in Comparison With HEXASIIL® (DTwP-HepB-IPV-Hib) Vaccine in Healthy Toddlers and Infants.

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 186 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

186

Planned (sponsor's estimate)

Start

Nov 1, 2026

Primary completion

Oct 2027

Study completion Oct 2027

Sponsor

Sponsor type
Industry
First posted
Oct 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 6 weeks, up to 24 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I/II, double-blind, randomized, active controlled, multi-centric clinical trial to assess the reactogenicity, safety and immunogenicity of a SIIPL DTwP-HepB-rPV-Hib vaccine in comparison with HEXASIIL® in healthy toddlers and infants. This trial is planned as a Phase I/II trial with two age cohorts to be enrolled sequentially, starting with healthy toddlers and subsequently extending to healthy infants. In Phase I of the trial, after at least one parent signs the informed consent and the participant's eligibility is confirmed, healthy toddlers aged 12-24 months will be randomized in a 2:1 ratio, to receive 0.5 mL of either of the vaccines intramuscularly in the upper anterolateral aspect of the thigh. Following vaccination, all toddlers will be observed at the site for minimum 30 (+15) minutes for any Iimmediate Adverse Event (IAE). Solicited Adverse Events (AEs) will be actively collected for 7 days post vaccination. Unsolicited AEs and Serious AEs will be collected throughout the trial from the time of signing informed consent till 28 days post vaccination. Blood samples for immunogenicity assessment will be obtained from all participating toddlers at Visit 1 (Prior to vaccination) and at Visit 4. A Data Safety Monitoring Board (DSMB) meeting will be convened for the evaluation of 7-day safety data in all participants. The DSMB shall review the safety data and provide recommendations to initiate Phase II of the trial. Additionally, Safety Review Comitte (SRC) will review the 24-hour safety data from the initial sentinel group (three participants) and give advice on progression to the subsequent enrolment in Phase I. After at least one parent signs the informed consent and the participant's eligibility is confirmed, all infants will be randomized in 2:1 ratio to receive a 3-dose primary vaccination series at 6, 10 and 14 weeks of age. Each participant will receive 0.5 mL of either vaccine intramuscularly in the upper anterolateral aspect of the thigh. Following each vaccination, all infants will be observed at the site for minimum 30 (+15) minutes for any IAEs. Active follow up for solicited AEs will be conducted over the 7-day period after each vaccination. Unsolicited AE/SAEs will be collected from signing of informed consent till Visit 10. Blood samples for immunogenicity assessment will be obtained from all participating infants at Visit 1 (Prior to vaccination) and at Visit 10.

Conditions

  • Diptheria Immunization
  • Tetanus Immunization
  • Pertussis Immunization
  • Hepatitis B Immunization
  • Haemophilus InfluenzaeType B Immunization
  • Polio Immunization

Interventions

  • Hexavalent (DTwP-HepB-rPV-Hib) VaccineBiological

    Hexavalent (DTwP-HepB-rPV-Hib) Vaccine

  • HEXASIILBiological

    Hexavalent (DTwP-HepB-IPV-Hib) Vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The incidence, severity and relationship of solicited AEs occurring up to 7 days following vaccination, unsolicited AEs and Serious Adverse Events till 28 days following vaccination in toddlersTime frame: 28 days
  2. The incidence, severity and relationship of solicited AEs occurring up to 7 days following each vaccination, unsolicited AEs and SAEs till 28 days post completion of a 3-dose primary vaccination series in infantsTime frame: 28 days post last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

    Dhaka, Bangladesh · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.